Cargando…

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer

(211)At is an α-emitter that has similar chemical properties to iodine and is used in targeted α-therapy. In the present study, we added ascorbic acid (AA) to (211)At solution to increase the radiochemical purity of astatide and evaluated its efficacy against differentiated thyroid cancer, which is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watabe, Tadashi, Kaneda-Nakashima, Kazuko, Liu, Yuwei, Shirakami, Yoshifumi, Ooe, Kazuhiro, Toyoshima, Atsushi, Shimosegawa, Eku, Fukuda, Mitsuhiro, Shinohara, Atsushi, Hatazawa, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2019
Materias:	Theranostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735285/ https://www.ncbi.nlm.nih.gov/pubmed/30796173 http://dx.doi.org/10.2967/jnumed.118.222638

Ejemplares similares

Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [(211)At] NaAt in Mice: A Revisit()
por: Liu, Yuwei, et al.
Publicado: (2020)

Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: A preclinical study in glioma bearing mice
por: Watabe, Tadashi, et al.
Publicado: (2020)

Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution
por: Shirakami, Yoshifumi, et al.
Publicado: (2021)

Comparison of the Therapeutic Effects of [(211)At]NaAt and [(131)I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model
por: Watabe, Tadashi, et al.
Publicado: (2022)

Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter
por: Kaneda-Nakashima, Kazuko, et al.
Publicado: (2022)

α‐Emitting cancer therapy using (211)At‐AAMT targeting LAT1
por: Kaneda‐Nakashima, Kazuko, et al.
Publicado: (2021)

Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer
por: Watabe, Tadashi, et al.
Publicado: (2021)

Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with (211)At Using Implanted Mouse Tumor
por: Yonekura, Yoshiharu, et al.
Publicado: (2022)

Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model
por: Liu, Yuwei, et al.
Publicado: (2021)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Targeted α-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
por: Watabe, Tadashi, et al.
Publicado: (2022)

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine
por: Aso, Ayaka, et al.
Publicado: (2023)

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
por: Watabe, Tadashi, et al.
Publicado: (2023)

Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection
por: Huang, Xuhao, et al.
Publicado: (2022)

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Monosodium Glutamate Reduces (68)Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
por: Rousseau, Etienne, et al.
Publicado: (2018)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
por: Wickstroem, Katrine, et al.
Publicado: (2019)

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
por: Loktev, Anastasia, et al.
Publicado: (2019)

Bone Marrow Absorbed Doses and Correlations with Hematologic Response During (177)Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
por: Hagmarker, Linn, et al.
Publicado: (2019)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
por: Schilham, Melline G.M., et al.
Publicado: (2021)

Preclinical Characterization of the Radioimmunoconjugate (111)In or (90)Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
por: Funase, Yuichi, et al.
Publicado: (2021)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy
por: Kato, Hiroki, et al.
Publicado: (2021)

Multi-modal 3D imaging of radionuclides using multiple hybrid Compton cameras
por: Omata, Akihisa, et al.
Publicado: (2022)

Performance demonstration of a hybrid Compton camera with an active pinhole for wide-band X-ray and gamma-ray imaging
por: Omata, Akihisa, et al.
Publicado: (2020)

Dimerization of the Sodium/Iodide Symporter
por: Thompson, Rebecca J., et al.
Publicado: (2019)

Quantitative measurement of (219)Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with (223)RaCl(2)
por: Ooe, Kazuhiro, et al.
Publicado: (2019)

Sodium iodide symporter-targeted gene therapy in glioblastoma
por: Nicola, Juan Pablo, et al.
Publicado: (2023)

Preserved Cerebral Oxygen Metabolism in Astrocytic Dysfunction: A Combination Study of (15)O-Gas PET with (14)C-Acetate Autoradiography
por: Macaisa, Carla Mari, et al.
Publicado: (2019)

Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
por: Katayama, Daisuke, et al.
Publicado: (2021)

Tumor microenvironment affects exogenous sodium/iodide symporter expression
por: Castillo-Rivera, Fabio, et al.
Publicado: (2020)

Decreased Expression of Thyroglobulin and Sodium Iodide Symporter Genes in Hashimoto's Thyroiditis
por: Popławska-Kita, Anna, et al.
Publicado: (2014)

Physiological sodium concentrations enhance the iodide affinity of the Na(+)/I(−) symporter
por: Nicola, Juan P., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pmm31bec5q4u40rhv2j8ol1dmn